We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma

This study is currently recruiting participants.
Verified June 2017 by Shanghai Longyao Biotechnology Inc., Ltd.
Sponsor:
ClinicalTrials.gov Identifier:
NCT03207178
First Posted: July 2, 2017
Last Update Posted: July 2, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Xuzhou Medical University
Shanghai Jiao Tong University School of Medicine
Information provided by (Responsible Party):
Shanghai Longyao Biotechnology Inc., Ltd.
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: February 28, 2020
  Estimated Primary Completion Date: February 28, 2019 (Final data collection date for primary outcome measure)